Quantitative analysis for Veradermics, Incorporated (MANE) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (41.0) (grade D). 30 signals analyzed (25 differentiated alt-data).
MANE stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $110.12 | $92.65 | $103.10 |
| 2026-05-08 | $110.79 | $105.23 | $106.14 |
| 2026-05-20 | $107.63 | $99.53 | $105.32 |
| 2026-06-02 | $104.04 | $97.61 | $98.18 |
| 2026-06-12 | $98.93 | $92.11 | $96.07 |
| 2026-06-25 | $121.45 | $114.01 | $119.37 |
| 2026-07-08 | $121.10 | $116.54 | $118.25 |
| 2026-07-20 | $115.50 | $104.45 | $106.04 |
| 2026-07-30 | $111.07 | $104.25 | $104.63 |
| 2026-08-12 | $111.86 | $104.98 | $109.05 |
| 2026-08-24 | $102.75 | $93.81 | $98.46 |
| 2026-09-03 | $100.98 | $95.42 | $97.75 |
How Veradermics, Incorporated stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| HNGE | Hinge Health, Inc. | $4.2B | — |
| NAMS | NewAmsterdam Pharma Company N.V. | $4.2B | — |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $4.1B | — |
| STVN | Stevanato Group S.p.A. | $4.8B | — |
View all Health Care stocks by valuation and signals →
Veradermics, Incorporated (MANE) scores Sell (41.0), and the composite conceals a 71-point disagreement between its dimensions. It is strongest on analyst consensus at 82 and competitive moat at 66, and weakest on technicals at 11. A stock can carry analyst consensus that high while technicals sits at 11; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 82 |
| competitive moat | 66 |
| technicals | 11 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Veradermics, Incorporated (MANE): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/MANE"><img src="https://stoquant.com/badge/MANE.svg" alt="Veradermics, Incorporated (MANE) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.